11 June 2015

Ludwig Cancer Research Opening a New Branch in Switzerland

New York, NY and Lausanne, Switzerland - June 11, 2015 - Ludwig Cancer Research is opening a new Branch in Lausanne, Switzerland. The Branch will be focused primarily on applied cancer immunology and the design of novel molecular and cell-based immunotherapies. It will also develop technologies enabling the efficient, safe application of those therapies to as many patients as possible. George Coukos will become the Director of the Lausanne Branch.

The Lausanne Branch will receive very generous support from the Canton of Vaud. It will be based at the University of Lausanne (UNIL) and the Lausanne University Hospital (CHUV), and operate in close collaboration with the new Swiss Cancer Center Lausanne (SCCL), a multi-institutional partnership involving the CHUV, UNIL, the ISREC Foundation and the Swiss Federal Institute of Technology (EPFL).

Ludwig Lausanne will initially establish a world-class scientific team through the creation of the Ludwig Human Tumor Immunology Discovery Engine in close connection with the CHUV. Researchers there will focus on studying the human tumor microenvironment, dissecting the cellular and molecular determinants of immune responses to human tumors and developing new molecular and cell-based approaches to cancer immunotherapy.

The Branch will also work closely with Geneva institutions and establish operations at the Swiss Institute of Bioinformatics and EPFL’s cancer and bioengineering research programs to develop the next generation of immune engineering technologies. In addition, significant investments by the Canton and the CHUV dedicated to establishing state-of-the-art clinical facilities, including a world-class manufacturing facility for the safe, swift manipulation and growth of immune cells, will enable a strong focus on the rapid clinical translation of novel therapies.

Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.